Diamonds and Dogs


Biogen (BIIB) surges 14% on positive mid-stage results for their Alzheimer's drug. Phase 2 trials showed deterioration slowed significantly in Alzheimer's patients who received Biogen's BAN2401 versus a placebo at 18 months. Patients in the trial were treated with the highest dose of the drug possible. Biogen also has another Alzheimer's treatment drug in its pipeline that is expected to go to Phase 3 trials in 2020.

PriceSmart (PSMT) not so smart. The warehouse club is down 10% after missing quarterly earnings estimates. The company did beat estimates by a penny, but revenue growth of 7.1% year/year to $782.2 million missed estimates. This was the fourth time in the trailing five quarters that this operator of membership warehouse clubs has missed expectations.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.